Results 11 to 20 of about 681,398 (156)

NTRK fusion-positive cancers and TRK inhibitor therapy [PDF]

Nature Reviews Clinical Oncology, 2018
NTRK gene fusions involving either NTRK1, NTRK2 or NTRK3 (encoding the neurotrophin receptors TRKA, TRKB and TRKC, respectively) are oncogenic drivers of various adult and paediatric tumour types.
Alexander Drilon, Emiliano Cocco, Maurizio Scaltriti   +2 more
exaly   +3 more sources

TRK Inhibitors: Tissue-Agnostic Anti-Cancer Drugs

Pharmaceuticals, 2021
Recently, two tropomycin receptor kinase (Trk) inhibitors, larotrectinib and entrectinib, have been approved for Trk fusion-positive cancer patients. Clinical trials for larotrectinib and entrectinib were performed with patients selected based on the ...
Sun-Young Han
doaj   +2 more sources

Rationale and design of ON-TRK: a novel prospective non-interventional study in patients with TRK fusion cancer treated with larotrectinib

BMC Cancer, 2022
Background Tropomyosin receptor kinase (TRK) fusion proteins resulting from neurotrophic tyrosine receptor kinase (NTRK) gene fusions are rare primary oncogenic drivers in a wide array of tumors.
James C. H. Yang, Marcia S. Brose, Gilberto Castro, Edward S. Kim, Ulrik N. Lassen, Serge Leyvraz, Alberto Pappo, Fernando López-Ríos, John A. Reeves, Marc Fellous, Frédérique Penault-Llorca, Erin R. Rudzinski, Ghazaleh Tabatabai, Gilles Vassal, Alexander Drilon, Jonathan Trent   +15 more
doaj   +2 more sources

Canadian Consensus for Biomarker Testing and Treatment of TRK Fusion Cancer in Pediatric Patients [PDF]

Current Oncology, 2021
Neurotrophic tyrosine receptor kinase gene fusions (NTRK) are oncogenic drivers present at a low frequency in most tumour types (80%) in a small number of rare tumours (e.g., infantile fibrosarcoma [IFS]) and considered mutually exclusive with other ...
Sébastien Perreault, Rose Chami, Rebecca J. Deyell, Dina El Demellawy, Benjamin Ellezam, Nada Jabado, Daniel A. Morgenstern, Aru Narendran, Poul H. B. Sorensen, Jonathan D. Wasserman, Stephen Yip   +10 more
doaj   +2 more sources

Basket trial of TRK inhibitors demonstrates efficacy in TRK fusion-positive cancers

Journal of Hematology & Oncology, 2018
Unlike many conventional cancers with preferential patterns of oncogenic genetic alterations, TRK fusions resulting from NTRK1/2/3 genetic alterations drive oncogenic transformations in more than 20 different malignancies over diverse tissue/cell ...
Yu Chen, Ping Chi
doaj   +2 more sources

Canadian Consensus for Biomarker Testing and Treatment of TRK Fusion Cancer in Adults

Current Oncology, 2021
The tyrosine receptor kinase (TRK) inhibitors larotrectinib and entrectinib were recently approved in Canada for the treatment of solid tumours harbouring neurotrophic tyrosine receptor kinase (NTRK) gene fusions.
D. Gwyn Bebb, Shantanu Banerji, Normand Blais, Patrice Desmeules, Sharlene Gill, Andrea Grin, Harriet Feilotter, Aaron R. Hansen, Martin Hyrcza, Monika Krzyzanowska, Barbara Melosky, Jonathan Noujaim, Bibiana Purgina, Dean Ruether, Christine E. Simmons, Denis Soulieres, Emina Emilia Torlakovic, Ming-Sound Tsao   +17 more
doaj   +2 more sources

The significance of Trk receptors in pancreatic cancer

Tumor Biology, 2017
This study investigated the Trk receptor family as a therapeutic target in pancreatic ductal adenocarcinoma and assessed their prognostic significance.
Matthew D Johnson, Brandon Stone, Bryan J Thibodeau, Andrew M Baschnagel, Sandra Galoforo, Laura E Fortier, Billie Ketelsen, Samreen Ahmed, Zakiya Kelley, Alaa Hana, Thomas G Wilson, John M Robertson, Robert P Jury, George D Wilson   +13 more
doaj   +2 more sources

Conversion Surgery After Administration of a TRK Inhibitor for Unresectable Parotid Gland Secretory Carcinoma [PDF]

Head and Neck
Takuma Matoba, Sho Iwaki, Takayuki Murase   +2 more
exaly   +2 more sources

Zurletrectinib is a next-generation TRK inhibitor with strong intracranial activity against NTRK fusion-positive tumours with on-target resistance to first-generation agents. [PDF]

Br J Cancer
While NTRK fusion-positive cancers can be exquisitely sensitive to first-generation TRK inhibitors, resistance inevitably occurs, mediated in many cases by acquired NTRK mutations.
Roa P, Foglizzo V, Harada G, Repetto M, Kulick A, de Stanchina E, de Marchena M, Auwardt S, Sayed Ahmed S, Bremer NV, Yang SR, Feng Y, Zhou C, Kong N, Liang R, Xu H, Zhang B, Bardelli A, Toska E, Ventura A, Drilon A, Cocco E.   +21 more
europepmc   +2 more sources

TRK fusion positive cancers: From first clinical data of a TRK inhibitor to future directions [PDF]

, 2020
Genetic alterations of neurotrophic tropomyosin or tyrosine receptor kinase (NTRK) 1/2/3 genes generate TRK fusion proteins have been reported in a variety of adult and child cancers from diverse cell/tissue lineages. Larotrectinib, a tumour-agnostic TRK
Sciortino M., De Logu F., Roviello G., Mini E., Nobili S., Massi D., D'Angelo A.   +6 more
core   +2 more sources